Answers - Finance

As a uranium play this stock is getting a lot of attention, which is driving the stock price up, despite the charts pointing to an overbo

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

ught situation. Conventional wisdom would tell us to be wary about investing in this stock at the moment but the question is; Are we in a

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

conventional market? And does conventional wisdom apply?

We have long been of the view that the price of uranium will hit $200.0 per pou

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

nd before this market peaks so at $72.0 per pound uranium still has a long way to go. The case for uranium has been laid out by many emin

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

nt analysts who can quote the number of reactors in the world (442) together with the proposals for future projects, which provides us wi

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

th a guide to uranium usage.

However why should the Chinese or any other nation for that matter actually disclose their true requirement

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

to us? If they did it could well cause a buying panic in the thinly traded uranium market. Surely it would make more sense to secure you

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

r future uranium supply before actually admitting that your energy needs dictated a ‘tripling’ in your uranium needs.

Suffering from bot

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

cynicism and suspicion leads us to believe that the demand for uranium is grossly underestimated and will come as a shock to the energy

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

world when the true figures start to appear from the current market haze.

This brings is to the uranium exploration and mining sector wh

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

ch is beginning to experience the effect of increased market activity. Not front page news yet but it will be.

Take for example a small

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

company called Santoy Resources limited, which has interests in a diverse range of resources such as Coalbed Methane, Coal, Oil & Gas and

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

Projects Available for Option, which include base metals and gold. A multi-metals explorer! Since October 2005 this stock has risen from

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

$0.10 to $1.00 with a myriad of gyrations taking place along the way.

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

-of-all-trades" target="_blank">Santoy Resources

What does this tell us? Well it indicates to us that investors are looking past hou

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

sehold names such Mega Uranium, Laramide and Cameco in the hope of unearthing a gem. It is not just Santoy that is now in the sights of t

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

e investor there are many similar examples scattered across Toronto’s venture exchange.

Back to conventional wisdom which would tell us

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

to beware such a small cap that has so far been thinly traded and if you your investment should do well take some money off the table, al

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

very sound advice. However, what if we are not in conventional waters and some of these stocks are about to become the toast of every af

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

ter dinner party chat? Will we regret taking a short-term profit because of conventional wisdom? For once we may need to turn a blind eye

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.answers.org.ua/article/102394/answers-Santoy-Resources-Ltd-Conventional-Wisdom.html">Santoy Resources Ltd: Conventional Wisdom?</a>

BB link (for phorums):
[url=http://www.answers.org.ua/article/102394/answers-Santoy-Resources-Ltd-Conventional-Wisdom.html]Santoy Resources Ltd: Conventional Wisdom?[/url]

The humble business card can be an excellent marketing tool if used wisely. This article suggests ways in which you can optimize the value of your business cards.

Are you looking at changing career? Are you looking for work? Have you been invited to a job interview? Are you looking for advice about interview techniques? If you have answered yes to any of these questions, this article may well be of help to you. I am going to give advice and information about how to be successful when attending a job interview.

What is quality traffic to your affiliate revenue? It is the lifeblood of the business model. It gives you your only opportunity to make a conversion. Simply put: If you don't have substantial quality traffic, you simply have no affiliate revenue.

Tags

Links

Answers - Santoy Resources Ltd: Conventional Wisdom?

Related Articles: